Press releases

Eisai completes rolling submission to the FDA of lecanemab for early Alzheimer’s disease under the accelerated approval pathway

May 10, 2022 - Regulatory press release

Stockholm, May 10, 2022 – BioArctic AB’s (publ) (Nasdaq Stockholm: BIOA B) partner Eisai announced today that they have completed the rolling submission to the U.S. ...

BioArctic receives new drug substance patent in the US for ABBV-0805 against Parkinson’s disease

May 6, 2022 - Other press release

Stockholm, May 6, 2022 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announced today that the US Patent and Trademark Office (USPTO) has granted a new ...

Report from annual general meeting in BioArctic AB (publ)

May 5, 2022 - Regulatory press release

Stockholm, Sweden, May 5, 2022 - BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) today held its Annual General Meeting. Due to Covid-19, the Annual General Meeting ...

Interim Report for the period January – March 2022

April 28, 2022 - Regulatory press release

Decision on marketing approval for lecanemab is approaching Events during the first quarter 2022 Eisai commenced submission of lecanemab data in Japan for a prior ...

Modeling published in Neurology and Therapy suggests that lecanemab could delay progression to Alzheimer’s dementia by several years

April 27, 2022 - Other press release

Stockholm, April 27, 2022 – BioArctic AB’s (publ) (Nasdaq Stockholm: BIOA B) partner Eisai announced today that an article about long-term health outcomes of the investigational ...

Invitation to presentation of BioArctic’s First Quarter Report for January – March 2022 on April 28 at 9.30 a.m. CET

April 20, 2022 - Other press release

Stockholm, Sweden, April 20, 2022 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) will publish the company’s First Quarter Report for January – March 2022 on ...

AbbVie terminates collaboration with BioArctic on alpha-synuclein portfolio

April 20, 2022 - Regulatory press release

Stockholm, April 20, 2022 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) has announced that the company’s partner AbbVie has decided to terminate its collaboration with ...

Notice of Annual General Meeting in BioArctic AB (Publ)

April 6, 2022 - Regulatory press release

The Board of BioArctic AB has resolved to convene an Annual General Meeting of shareholders to be held on Thursday, 5 May 2022

BioArctic publishes the Annual Report for 2021

March 31, 2022 - Regulatory press release

Stockholm March 31, 2022 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) hereby announces that the Swedish version of the 2021 Annual Report has been published. ...

BioArctic and Eisai presented latest data regarding lecanemab at the AD/PD[TM] 2022 conference

March 21, 2022 - Other press release

Stockholm, March 21, 2022 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) today announced data on the drug candidate lecanemab (BAN2401) – an investigational anti-amyloid-beta ...

Latest lecanemab data to be presented at the AD/PD™ congress

March 11, 2022 - Other press release

Stockholm, March 11, 2022 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announced today that the company and its collaboration partner Eisai will both present data ...

The Nomination Committee’s proposal for the election of board members in BioArctic AB

March 9, 2022 - Regulatory press release

Stockholm March 9, 2022 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) hereby announces that the Nomination Committee for BioArctic AB (publ) presents the following proposals ...

Eisai initiates submission of application data of lecanemab under the prior assessment consultation system in Japan with the aim of an earlier regulatory approval

March 4, 2022 - Regulatory press release

Stockholm, March 4, 2022 - BioArctic AB:s (publ) (Nasdaq Stockholm: BIOA B) partner Eisai has initiated a submission to the Pharmaceuticals and Medical Devices Agency (PMDA) ...

BioArctic continues to build its commercial organization

February 18, 2022 - Other press release

Stockholm, February 18, 2022 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) continues to build the Nordic commercial organization ahead of a potential launch of the ...

Interim Report for the period October – December 2021

February 3, 2022 - Regulatory press release

A time of hope for Alzheimer’s patients

Invitation to presentation of BioArctic’s Full Year Report for January – December 2021 on February 3 at 9.30 a.m. CET

January 27, 2022 - Other press release

Stockholm, Sweden, January 27, 2022 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) will publish the company’s Full Year Report for January – December 2021 on Thursday, February ...

DIAN-TU enrolls first subject for the Tau NexGen study with lecanemab as back-ground anti-amyloid treatment

January 19, 2022 - Other press release

Stockholm, January 19, 2022 - BioArctic AB:s (publ) (Nasdaq Stockholm: BIOA B) partner Eisai announced today that the Dominantly Inherited Alzheimer Network Trials Unit (DIAN-TU), led ...